BNP Paribas Financial Markets Purchases Shares of 151,906 Protara Therapeutics, Inc. (NASDAQ:TARA)

BNP Paribas Financial Markets acquired a new position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 151,906 shares of the company's stock, valued at approximately $802,000. BNP Paribas Financial Markets owned approximately 0.74% of Protara Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TARA. Geode Capital Management LLC increased its holdings in shares of Protara Therapeutics by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after purchasing an additional 9,553 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in Protara Therapeutics by 90.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company's stock worth $195,000 after buying an additional 17,572 shares during the period. HBK Investments L P bought a new position in shares of Protara Therapeutics during the 4th quarter valued at about $106,000. Dimensional Fund Advisors LP bought a new position in Protara Therapeutics in the fourth quarter valued at approximately $111,000. Finally, Oppenheimer & Co. Inc. boosted its stake in Protara Therapeutics by 12.4% in the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company's stock worth $1,064,000 after purchasing an additional 22,301 shares during the period. 38.13% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Protara Therapeutics

In related news, insider Jacqueline Zummo sold 21,224 shares of the firm's stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the transaction, the insider now directly owns 98,861 shares of the company's stock, valued at $447,840.33. This trade represents a 17.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.40% of the company's stock.

Protara Therapeutics Price Performance

NASDAQ TARA opened at $3.25 on Thursday. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The business has a fifty day moving average price of $3.88 and a two-hundred day moving average price of $4.14. The stock has a market capitalization of $125.39 million, a PE ratio of -1.15 and a beta of 1.73.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.18. As a group, sell-side analysts expect that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Scotiabank began coverage on Protara Therapeutics in a research report on Wednesday, April 16th. They set a "sector outperform" rating and a $12.00 price target for the company. Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a research report on Friday, March 14th. They issued an "overweight" rating on the stock. HC Wainwright reissued a "buy" rating and set a $23.00 price target on shares of Protara Therapeutics in a report on Monday, April 28th. Finally, Lifesci Capital started coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 price objective for the company. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $20.40.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.

Want to see what other hedge funds are holding TARA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.